Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity

• Published in: Biomedicine & pharmacotherapy Vol. 129; p. 110462
• Main Authors: Cao, Dai, Zhu, Guo-Yuan, Lu, Yan, Yang, Aiping, Chen, Die, Huang, Hui-Jie, Peng, Shu-Xian, Chen, Li-Wen, Li, Ying-Wei
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.09.2020
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Animals; Antineoplastic Agents - pharmacology; Cell Line, Tumor; Cell Movement - drug effects; Epithelial to mesenchymal transition; Epithelial-Mesenchymal Transition - drug effects; Female; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Luteolin - pharmacology; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Proteolysis; Signal Transduction; Trans-Activators - genetics; Trans-Activators - metabolism; Transcription Factors - genetics; Transcription Factors - metabolism; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Triple-negative breast cancer; Tumor Burden - drug effects; YAP/TAZ activity; PR; SRB; DMSO; IHC; HTS; YAP; HIF1/2; CYR61; CTGF; Triple-negative breast cancer; DMEM; FBS; IC50; WWTR1/TAZ; TGF-β; Luteolin; TNBC; NF- κ B; CSCs; TEADs; PBS; Epithelial to mesenchymal transition; DAB; EGF; STAT3; DAPI; ER; EMT; PVDF; TEAD; YAP/TAZ activity; Her2

Triple-negative breast cancer (TNBC) is a highly lethal subtype of breast cancer associated with early relapse and metastasis. Epithelial to mesenchymal transition (EMT) plays pivotal roles in the progression of TNBC, including inducing cancer stem cell (CSC) properties, chemoresistance, tumor metas...